Rhythm Pharmaceuticals announced a change in its Board of Directors with Kim Popovits joining as a new director and Ed Mathers stepping down. Popovits brings over 40 years of experience in life sciences, including leadership roles at Genomic Health and Genentech, which is expected to strengthen Rhythm's commercialization and governance capabilities. Mathers, who served since 2013, was thanked for his strategic guidance during the company's growth. This leadership update comes as Rhythm continues to advance its rare disease treatments, including its FDA-approved drug IMCIVREE for obesity related to genetic conditions.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Rotork PLC has accepted a £4.1 billion takeover bid from Swiss engineering group ABB, offering shareholders 506p per share, a 73% premium over the previous closing price. The acquisition will enhance ABB's industrial automation business by adding Rot...
Alexandria Real Estate Equities (ARE) is struggling with oversupply and vacancy rates exceeding 30% in key life science markets like Boston, San Francisco, and San Diego. This has caused an 80% decline in its stock price from its peak. The company's ...
ASML Holdings has raised its 2026 revenue guidance midpoint from €38 billion to €44 billion and increased its gross margin midpoint from 52% to 55%, reflecting strong growth prospects. The analyst maintains a Buy rating and raises the price target fr...
Labcorp is considered a buy due to its effective rollup strategy in a fragmented lab testing industry, driving steady and predictable growth. Automation is reducing operational costs, helping to counteract healthcare pricing pressures. The company no...
